ZA966075B - Protein formulation. - Google Patents

Protein formulation.

Info

Publication number
ZA966075B
ZA966075B ZA9606075A ZA966075A ZA966075B ZA 966075 B ZA966075 B ZA 966075B ZA 9606075 A ZA9606075 A ZA 9606075A ZA 966075 A ZA966075 A ZA 966075A ZA 966075 B ZA966075 B ZA 966075B
Authority
ZA
South Africa
Prior art keywords
protein formulation
formulation
protein
Prior art date
Application number
ZA9606075A
Other languages
English (en)
Inventor
James Andya
Jeffrey L Cleland
Chung C Hsu
Xanthe M Lam
David E Overcashier
Steven J Shire
Janet Yu-Feng Yang
Sylvia Sau-Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA966075(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA966075B publication Critical patent/ZA966075B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA9606075A 1995-07-27 1996-07-17 Protein formulation. ZA966075B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27

Publications (1)

Publication Number Publication Date
ZA966075B true ZA966075B (en) 1998-01-19

Family

ID=24021032

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA9606075A ZA966075B (en) 1995-07-27 1996-07-17 Protein formulation.
ZA9606240A ZA966240B (en) 1995-07-27 1996-07-23 Methods for treatment of allergic asthma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA9606240A ZA966240B (en) 1995-07-27 1996-07-23 Methods for treatment of allergic asthma.

Country Status (16)

Country Link
EP (1) EP0841946B2 (fr)
JP (1) JP4153560B2 (fr)
CN (2) CN101172099B (fr)
AR (1) AR003468A1 (fr)
AT (1) ATE225185T1 (fr)
AU (1) AU715338B2 (fr)
CA (1) CA2226624C (fr)
DE (1) DE69624116T3 (fr)
DK (1) DK0841946T4 (fr)
ES (1) ES2186796T5 (fr)
IL (1) IL122733A (fr)
MX (1) MX9800760A (fr)
PT (1) PT841946E (fr)
RU (1) RU2229288C2 (fr)
WO (1) WO1997004807A1 (fr)
ZA (2) ZA966075B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6630140B1 (en) * 1998-03-10 2003-10-07 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
CA2505316C (fr) 2002-11-08 2014-08-05 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
EP1558647B1 (fr) 2002-11-08 2015-06-10 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
WO2008092993A1 (fr) * 2007-01-29 2008-08-07 Valtion Teknillinen Tutkimuskeskus Procédé de fabrication de nouveaux réactifs à base d'ige
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (fr) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Formulations d'hormones parathyroïdiennes et leurs utilisations
EP2222315B1 (fr) * 2007-12-21 2013-04-24 Inspiration Biopharmaceuticals, Inc. Formulations stabilisées de facteur ix contenant du tréhalose
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
EP2362767B1 (fr) * 2008-10-29 2017-12-06 Ablynx N.V. Formulations de molécules de liaison d'antigène monodomaines
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
AU2010332958B2 (en) 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
JP6014116B2 (ja) * 2011-03-31 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
WO2013063284A1 (fr) * 2011-10-25 2013-05-02 Onclave Therapeutics Formulations d'anticorps et procédés correspondants
RU2683823C2 (ru) * 2013-09-27 2019-04-02 Ханми Фарм. Ко., Лтд. Препарат гормона роста человека длительного типа
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
HUE056849T2 (hu) 2014-11-21 2022-03-28 Ascendis Pharma Endocrinology Div A/S Hosszú hatástartalmú növekedési hormon adagolási formák
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CA3060581A1 (fr) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019019998A1 (fr) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 Composition pharmaceutique à base d'un complexe protéique d'il-15 et utilisations correspondantes
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
US20230250191A1 (en) 2020-07-10 2023-08-10 Shanghai Jemincare Pharmaceutical Co., Ltd. Anti-ige engineered antibody and application thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
EP0617127A1 (fr) * 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Epitopes antigéniques des immunoglobulines IgE liées aux cellules B
JPH07507923A (ja) * 1992-03-20 1995-09-07 イムネット ヒトモノクローナル抗体およびヒトモノクローナル抗体製造法
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
EP1452542A3 (fr) * 1992-09-24 2007-05-02 Novartis AG Anticorps monoclonaux humains transformés contre l'IgE
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
CN101172100A (zh) 2008-05-07
ATE225185T1 (de) 2002-10-15
RU2229288C2 (ru) 2004-05-27
CA2226624A1 (fr) 1997-02-13
CN101172099A (zh) 2008-05-07
ES2186796T5 (es) 2009-04-01
CA2226624C (fr) 2013-07-16
ZA966240B (en) 1998-01-23
ES2186796T3 (es) 2003-05-16
JPH11510172A (ja) 1999-09-07
DK0841946T3 (da) 2003-02-10
IL122733A0 (en) 1998-08-16
IL122733A (en) 2001-09-13
AU6638196A (en) 1997-02-26
DK0841946T4 (da) 2009-02-16
EP0841946B1 (fr) 2002-10-02
EP0841946B2 (fr) 2008-10-15
CN101172099B (zh) 2012-02-15
AU715338B2 (en) 2000-01-20
DE69624116D1 (de) 2002-11-07
JP4153560B2 (ja) 2008-09-24
PT841946E (pt) 2003-02-28
AR003468A1 (es) 1998-08-05
MX9800760A (es) 1998-04-30
DE69624116T3 (de) 2009-07-09
EP0841946A1 (fr) 1998-05-20
DE69624116T2 (de) 2003-06-18
WO1997004807A1 (fr) 1997-02-13

Similar Documents

Publication Publication Date Title
ZA966075B (en) Protein formulation.
ZA966148B (en) Novel formulation.
HK1011856A1 (en) Cement formulation.
ZA967315B (en) Biphenylamides.
ZA962338B (en) Oral 2-methyl-thieno-benzodiazepine formulation.
ZA967745B (en) Pharmaceutical formulations.
ZA969722B (en) Pharmaceutical formulations.
ZA965190B (en) Pharmaceutical composition.
HK1016472A1 (en) Activated protein c formulations.
MX213417B (es) Fenilpiridazinonas.
CY2359B1 (en) Pharmaceutical formulation.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
EP0578819A4 (fr) Proteine apparentee a icam.
DE69610844D1 (en) Hydroformylierungsverfahren.
GB9510830D0 (en) Proteins
ZA968081B (en) Pharmaceutical composition.
ZA966399B (en) Endothelin-receptor-antagonists.
AU7520396A (en) Abl-interactor protein
ZA968185B (en) Protein.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA966750B (en) Halogenobenzimidazoles.
ZA967314B (en) Carbamoylcarboxamides.
GB9622436D0 (en) Protein
ZA9610467B (en) OB protein derivatives.